Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-07-11
2006-07-11
Zara, Jane (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C514S04400A
Reexamination Certificate
active
07074915
ABSTRACT:
The invention relates to an antisense oligonucleotide targeted to the coding region of the human acetylcholinesterase (AChE), which selectively suppresses the AChE-R isoform of the enzyme. The antisense oligonucleotide is intended for use in the treatment and/or prevention of neuromuscular disorders, preferably myasthenia gravis. In addition, it can penetrate the blood-brain barrier (BBB) and destroy AChE-R within central nervous system neurons, while also serving as a carrier to transport molecules across the BBB.
REFERENCES:
patent: 5455044 (1995-10-01), Kim et al.
patent: 5558852 (1996-09-01), Bigner et al.
patent: 5891725 (1999-04-01), Soreq et al.
patent: 6110742 (2000-08-01), Soreq et al.
patent: WO 9822132 (1998-05-01), None
patent: WO 9826062 (1998-06-01), None
patent: WO 0136627 (2001-05-01), None
Soreq et al. Antisense oligonucleotide inhibition of acetylcholinesterase gene expression induces progenitor cell expansion and suppresses hematopoietic apoptosis ex vivo. Aug. 1994 Proc. Natl. Acad. Sci. USA, vol., 91. pp. 7907-7911 (esp. 7908).
Webster's II New Riverside University Dictionary 1994 The Riverside Publishing Company (see p. 1194).
Abe et al. (1998)Antivir. Chem. Chemother.9, 253-62.
Agrawal S. and Kandimalla E.R. (2000)Mol. Med. Today, 6, 72-81.
Bai et al. (1998) AnnThorac. Surg.66, 814-9.
Ben Nathan D. et al. (1991)Life .Sci.48, 1493-1500.
Berrouschot et al. (1997)Crit. Care Med.25, 1228-35.
Bochot et al. (1998)Pharm. Res.15, 1364-9.
Boneva, N. et al. (2000)Muscle&Nerve 23, 1204-8.
Capaccioli et al. (1993)Biochem. Biophys. Res. Comm.197, 818.
Cohen, O. et ;al. (2002)Mol. Psychiatry7, 874-885.
Conaty et al. (1999)Nucleic Acids Res.27, 2004-2407.
Crooke S. T. (2000)Methods Enzymol.313, 3-45.
de Angelis, L.M. (2001) JV.Engl. JMed.344(2), 114-123.
Drachman, D.B. (1994)N Eng J Med 330, 1797-810.
Galyam, N. et al. (2000)Antisense Nucl Acid Drug Dev 11, 51-57.
Gerster et al. (1998)Anal.Biochem.262, 177-84.
Goldstein and Betz (1986)Scientific American, Sep., pp. 70-79.
Grifman, M., and Soreq, H. (1997)Antisense Nucleic Acid Drug Dev 7, 351-9.
Grosari D. et al. (2001)Mol. Med.7, 93-105.
Hall and Sanes (1993)Cell72 /Neuron vol. 10 (Suppl.), 99-121.
Haseloff and Gerlach (1998)Nature334, p. 585-591.
ImperatoA. et al. (1991)Brain Res.538, 111-117.
Kanamaru et al. (1998) J.Drug Target5, 235-46.
Kita and Saito (1991)Int. J. Cancer80, 553-8.
Koenigsberger C. et al. (1997)J. Neurochem.69, 1389-1397.
Legay et al. (1993),J. Neurochem.60(1), 337-346.
Lesnik, E.A. & Freier, S.M. (1998)Biochemistry37, 6991-7.
Monia, B. P. (1997)Ciba Found. Symp. 209, 107-119.
Nakamura et al.(1998)Gene Ther.5, 1455-61.
Noguchi et al. (1998)FEBS Lett.433, 169-73.
Pere Ruiz (1999)Antisense Nucleic Acid Drug Dev., 9, 33.
Quattrone et al. (1995)Biochemica1, 25.
Rachinsky et al. (1990)Neuron5(3), 317-327.
Sarver et al. (1990) Science 247, p. 1222.
Seidman S. et al. (1999)Antisense Nucl. Acid Drug Devel, 9, 333-340.
Sharma H.S. et al. (1992)Prog. Brain Res.91, 189-196.
Shoji et al. (1998)J. Drug Target5, 261-73.
Soni et al. (1998)Hepatology, 28, 1402-10.
Soreq, H., and Seidman, S. (2001)Reviews Neuroscience 2, 294-302.
Soukchareun et al. (1998)Bioconjug. Chem.9, 466-75.
Sugawa et al. (1998)J. Neurooncol.39, 237-44.
Tavitan et al. (1998)Nat Med 4(4): 467-71.
Triggs et al. (1992)Muscle Nerve15, 267-72.
Vincent A. (1999)Curr. Opin Neurol.12, 545-551.
Waelti et al. (1998)Int. J. Cancer, 77, 728-33.
Wang, J. (1998)Controlled Release53, 39-48.
Wittbrodt (1994)Arch. Intern. Med., 157, 399-408.
Xu et al. (1999)Endocrinology, 140, 2134-44.
Yang et al. (1998)Circ. Res.83, 552-9.
Andres et al., Acetylcholinesterase-transgenic mice display embryonic modulations in spinal cord choline acetyltransferase and neurexin Iβ gene expression followed by late-onset neuromotor deterioration.Proc. Natl. Acad. Sci. USA.94:8173-8178 (1997).
Ben Aziz-Aloya et al., Expression of human acetylcholinesterase promoter-reporter construct in developing neuromuscular junctions ofXenopusembryos.Proc. Natl. Acad. Sci. USA.90:2471-2475 (1993).
Ellman et al., A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity.Biochemical Pharmacology. 7:88-95 (1961).
Friedman et al., Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response.Nature Medicine. 2:1382-1385 (1996).
Kaufer et al., Acute stress facilitates long-lasting changes in cholinergic gene expression.Nature. 393:373-377 (1998).
Koenisberger et al., Neurite Differentiation Is Modulated in Neuroblastoma Cells Engineered for Altered Acetylcholinesterase Expression.J. Neurochem. 69:1389-1397 (1997).
Lev-Lehman et al., Synaptogenesis and Myopathy Under Acetylcholinesterase Overexpression.J. Mol. Neurosci. 14:93-105 (2000).
Meshorer et al., Alternative Splicing and Neuritic mRNA Translocation Under Long-Term Neuronal Hypersensitivity.Science. 295:508-512 (2002).
Meyer et al., Cationic Liposomes Coated with Polyethylene Glycol As Carriers for Oligonucleotides.J. Biol. Chem.273(25):15621-15627 (1998).
Ratajczak et al.,In vivotreatment of human leukemia in ascidmouse model with c-myb antisense oligodeoxynucleotides.Proc. Natl. Acad. Sci. USA.89:11823-11827 (1992).
Rossi et al., Localization of “Non-extractable” Acetycholinesterase to the Vertebrate Neuromuscular Junction.J. Bio. Chem.268(25):19152-19159 (1993).
Seidman et al., Overexpressed Monomeric Human Acetylcholinesterase Induces Subtle Ultrastructural Modifications in Developing Neromuscular Junctions ofXenopus laevisEmbryos,J. Neurochem.62(5):1670-1681 (1994).
Seidman et al:, Synaptic and Epidermal Accumulations of Human Acetylcholinesterase Are Encoded by Alternative 3′-Terminal Exons.Mol. And Cell. Biol.15(6):2993-3002 (1995).
Shapira et al., A transcription-activating polymorphism in theACHEpromoter associated with acute sensitivity to ant-acetylcholinesterases.Human Molecular Genetics.9(9):1273-1281 (2000).
Soreq et al., Molecular cloning and construction of the coding region for human acetylcholinesterase reveals a G+C-rich attenuating structure.Proc. Natl. Acad. Sci. USA.87:9688-9692 (1990).
Sternfeld et al., Acetylcholinesterase Enhances Neurite Growth and Synapse Development through Alternative Contributions of Its Hydrolytic Capacity, Core Protein, and Variable C Termini.J. Neurosci.18(4):1240-1249 (1998).
Sternfeld et al., Excess “read-through” acetylcholinesterase attenuates but the “synthetic” variant intensifies neurodeterioration correlates.Proc. Natl. Acad. Sci. USA.97(15)8647-8652 (2000).
Shohami et al., Antisense prevention of neuronal damages following head injury in mice.J. Mol. Med.78:228-236 (2000).
Evron Tama
Saidman, legal representative Jackiline
Soreq Hermona
Ashen Jon B.
Cooper & Dunham LLP
White, Esq. John P.
Yissum Research Development Company of the Hebrew University of
Zara Jane
LandOfFree
Antisense oligonucleotide against human acetylcholinesterase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotide against human acetylcholinesterase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotide against human acetylcholinesterase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3532484